Henry Schein Inc. (HSIC) Dividend Safety Gauge & 10-Year DRIP Compounder

$84.88 -1.80% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $84.44

Henry Schein Inc. (HSIC) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ β€’ SELL / AVOID Cap $9.46B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HSIC Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is HSIC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Henry Schein Inc. (NASDAQ: HSIC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $84.88 (-1.80% 1D, market cap $9.46B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, HSIC ranks #181 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does HSIC compare to OSCR and CAI in the Health Care sector?
β–Ό

Within the Health Care sector (Medical Specialities), HSIC carries a Roarable D+ (58/100 RQD), trailing P/E of 23.0x, gross margin of 31.1%, and ROIC of 11.2%. By comparison, OSCR (Oscar Health Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $9.37B) and CAI (Caris Life Sciences Inc.) posts a B grade (73/100 RQD, P/E N/A, ROIC 4.4%, cap $9.70B). Among the 5-stock peer group, MOH leads on earnings multiple (22.0x) while MOH leads on capital efficiency (17.2% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HSIC?
β–Ό

Per HSIC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-27, CIK 0001000228), Henry Schein Inc. generated $13.18B in revenue (+4.0% YoY), $419.0M in net income, and $118.7M in free cash flow against $11.21B in total assets and $2.89B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $84.45 (-0.51%)🧬 Disciplined Float (-0.04% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 0.9% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY β€’ 52.7% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D+
025507510058
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ Β· Rk C
Cash (9)Whales (11)SEC (14)Macro (12)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
$100 Bull$85 Base$66 Bear
πŸ“¬ FREE HSIC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for HSIC)Realized 20D OHLCV Swing Band: Β±4.8%
Deterministic 5-Pillar Attribution (58/100 Composite)
πŸ” WHY HSIC SCORES 58/100 (D+) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (24% of score)

Altman Z-Score 2.81 (WATCH ZONE (1.8–3.0)) β€’ Piotroski F-Score 7/9

β–² #2 Bullish Driver: Macro Regime Fit+12/20 pts (21% of score)

FRED Regime Γ— Technicals: 70% of 52W Range β€’ RSI-14 at 47.5 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Cash Engine Quality9/20 pts (-11 pt drag)

Capital intensity & 5% operating margin leave 11 pts on the table

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
66
Grade B-$85.56-0.6% Next Q
Q2 (-2Q)
63
Grade C+$85.01-0.1% Next Q
Q3 (-1Q)
61
Grade C$84.96-0.1% Next Q
Current
58
Grade D+$84.88+0% Hist 90D Ξ±
Trajectory: B- (66) β†’ D+ (58)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the HSIC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 58/100 (D+) score, HSIC faces multiple-compression risk if 23.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.04% YoY Shares) β€” any gross margin slip below 28.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($86.33) or 200D SMA ($81.17) invalidates the momentum regime and cuts Target Base ($84.88) toward Bear Floor ($66.21).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HSICβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œHSIC Beats Next Quarter EPS Consensus (Dec 26, 2026) & Holds Above 200D SMA”
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $17,081

Est. Year-10 Shareholder Yield: $102/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HSIC)

  • βœ“Walkthrough of HSIC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HSIC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +17.86%⚑ TESTING RESISTANCE
2026-11-03O $86.44H $86.44L $84.88C $84.88VOL 1.20M
RES: $86.59SUP: $78.03SMA50: $86.33SMA200: $81.17
$93.82$87.01$80.21$73.40$66.59RES $86.59SUP $78.03$84.882026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HSIC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
16.8%/yr Implied 5Y Growth

vs. +4.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HSIC today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for HSIC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HSIC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HSIC)

1. Head-to-Head Health Care Peer Comparison (HSIC vs. OSCR, CAI, MOH, GRAL)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Henry Schein Inc. (HSIC) ranks #181 by composite RQD confidence (58/100, grade D+) and #116 by equity capitalization ($9.46B). Within this direct 5-issuer industry benchmark cohort, MOH leads on earnings valuation at 22.0x trailing P/E, while MOH leads on capital efficiency and profitability with 17.2% ROIC and 13.1% gross margin. CAI currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with HSIC at 58/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
HSIC ACTIVE
Henry Schein Inc.
D+ 58/100 23.0x 31.1% 11.2% -1.80% $9.46B Benchmark Subject
OSCR
Oscar Health Inc.
D+ 53/100 β€” β€” -35.0% -1.36% $9.37B /oscr-vs-hsic β†’
CAI
Caris Life Sciences Inc.
B 73/100 β€” β€” 4.4% -5.01% $9.70B /cai-vs-hsic β†’
MOH
Molina Healthcare Inc
D+ 57/100 22.0x 13.1% 17.2% +2.93% $10.69B /moh-vs-hsic β†’
GRAL
GRAIL Inc.
D+ 54/100 β€” β€” -18.0% -9.75% $6.41B /gral-vs-hsic β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-27 β€’ CIK 0001000228

In its most recent audited fiscal period (FY2025, filed 2025-12-27), Henry Schein Inc. (HSIC) reported GAAP revenue of $13.18B (+4.0% vs. FY2024 revenue of $12.67B , and +6.8% cumulative change since FY2023) , GAAP net income of $419.0M, operating cash flow of $712.0M, and free cash flow of $118.7M (-57.3% YoY). On the balance sheet, HSIC closed FY2025 with $11.21B in total assets against $2.89B in total debt (Altman Z-Score: 2.81, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-27 $13.18B $419.0M $712.0M $118.7M $11.21B $2.89B
FY2024 (FY) 2024-12-28 $12.67B $398.0M $848.0M $277.7M $10.22B $2.42B
FY2023 (FY) 2023-12-30 $12.34B $436.0M $500.0M -$55.3M $14.81B $3.46B

3. HSIC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HSIC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Henry Schein Inc. (NASDAQ: HSIC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $84.88 (-1.80% 1D, market cap $9.46B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, HSIC ranks #181 in composite RQD confidence.

How does HSIC compare to OSCR and CAI in the Health Care sector?

Within the Health Care sector (Medical Specialities), HSIC carries a Roarable D+ (58/100 RQD), trailing P/E of 23.0x, gross margin of 31.1%, and ROIC of 11.2%. By comparison, OSCR (Oscar Health Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -35.0%, cap $9.37B) and CAI (Caris Life Sciences Inc.) posts a B grade (73/100 RQD, P/E N/A, ROIC 4.4%, cap $9.70B). Among the 5-stock peer group, MOH leads on earnings multiple (22.0x) while MOH leads on capital efficiency (17.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HSIC?

Per HSIC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-27, CIK 0001000228), Henry Schein Inc. generated $13.18B in revenue (+4.0% YoY), $419.0M in net income, and $118.7M in free cash flow against $11.21B in total assets and $2.89B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HSIC trading relative to its 50-day, 200-day, and 52-week technical levels?

HSIC last traded at $84.88 (-1.80% on volume of 1,195,526 shares), positioning the stock -1.68% below its 50-day simple moving average ($86.33) and +4.57% above its 200-day simple moving average ($81.17). Across its 52-week range of $68.00 to $92.18, HSIC sits at the 69.8% percentile with a 14-day RSI of 47.5 (NEUTRAL RANGE) and an implied next-earnings move of Β±4.8% ($80.81 to $88.95).

HSIC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Does HSIC pay a dividend and is it safe?

Henry Schein Inc. (HSIC) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

ROARABLE RATING BRIEF β€’ RQD 58/100 (D+) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

HSIC β€” Henry Schein Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:16:53Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, HSIC scores 60 out of 100, earning a C- grade and the verdict "Roarable Hold β€” Cautious Neutral." The five pillars break down as follows. Fundamental Cash Engine scores 9 of 20 (ROIC 11.2%; FCF yield 1.23%), the weakest pillar and the one most directly tied to whether the business is generating cash relative to its price. Whale 13F Flow scores 13 of 20 (institutional accumulation and options positioning), indicating moderate institutional interest. Insider Conviction scores 12 of 20 (SEC Form 4 and Congressional PTR cluster flow), a middling reading. Macro Regime Fit scores 12 of 20 (Beta 0.89; sector sensitivity), suggesting a lower-than-market beta profile. Forensic Balance Sheet scores 14 of 20 (Altman Z 2.81; Piotroski F 7/9; Debt/Equity 0.83), the strongest pillar.

For a prospective investor, the upside case rests mainly on balance-sheet resilience and a below-market beta, which may cushion drawdowns. The valuation tradeoff is that the stock trades at a trailing P/E of 23 and an EV/EBITDA of 9.5 against a thin 1.23% FCF yield, so the market is paying for earnings the cash flow has not yet fully confirmed. The 60 score and "Hold" verdict reflect that mix: financial strength without a compelling cash-yield entry point.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$86.44$9.63B2321.49.53.760%0.89$63.04 - $92.1811.2%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$13184.0M$653.0M$419.0MN/A$118.7MN/A$2889.4M
FY 2024$12673.0M$621.0M$398.0MN/A$277.7MN/A$2421.4M
FY 2023$12339.0M$615.0M$436.0MN/A$-55.3MN/A$3464.8M

Per the SEC financials, revenue rose from $12339.0M in FY 2023 to $13184.0M in FY 2025, while net income moved from $436.0M to $419.0M over the same span. Market data reports a gross margin of 31.1%, an operating margin of 5%, and a net margin of 3.2%, with ROIC of 11.2%. The Roarable RQD rating cites an Altman Z-Score of 2.81 and a Piotroski F-Score of 7/9, and a Debt/Equity ratio of 0.83. Free cash flow fell from $277.7M in FY 2024 to $118.7M in FY 2025, and debt rose from $2421.4M to $2889.4M over the same period.

Recent Catalysts & News Wire Analysis

Six headlines appear in the news feed, all tagged to HSIC:

  • Yahoo Finance coverage asking whether value investors should buy the stock (YELLOW, Market Wire).
  • TradingView coverage previewing a Q3 earnings report (YELLOW, Market Wire).
  • Yahoo Finance coverage of renewed market attention (YELLOW, Market Wire).
  • The Globe and Mail coverage comparing Q2 earnings with other dental equipment and technology stocks (YELLOW, Market Wire).
  • TradingView coverage of a 12-month price target cut to $97.27, implying 16% upside (RED, Risk Watch).
  • Simply Wall Street coverage of why the stock is drawing attention (YELLOW, Market Wire).

The single RED item is the price-target cut, flagged as a risk watch item. The Q3 earnings preview is the nearest scheduled catalyst. The Butterfly Supply-Chain Graph reports no proprietary signals and no links.

Open Questions

  • What is the company's product mix, customer base, and revenue model? The source data gives only the sector and industry classification.
  • Why is EPS reported as N/A for all three fiscal years, and what is cash on hand? Both are missing from the financials table.
  • What drove the decline in FCF from $277.7M to $118.7M, and does the debt increase relate to that change?
  • Which analyst firms issued the price-target cut, and what is the consensus rating?
  • What is the Q3 earnings date and consensus expectation referenced in the preview headline?

HSIC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Henry Schein Inc. (HSIC) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to HSIC Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HSIC Bull vs. Bear Conversation Board β€” What's Your Call at $84.88?

πŸ‚ 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HSIC 🐻 50% BEARISH CONVICTION
1. Pick Your Side on HSIC:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk βš–οΈ DEBATE HOST 🎯 Target: $93.36 (+8.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is HSIC (C- β€’ RQD 60/100) a Buy at $86.44?

Welcome to the HSIC (Henry Schein Inc.) Roar Pit. Current RQD Composite is 60/100 (Roarable Hold β€” Cautious Neutral) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $70.02 (-19.0%)
Spot @ $86.44

Pump the brakes on HSIC β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on HSIC, but look at what you are paying: 23.0x trailing P/E with 31.1% gross margins. Unless Henry Schein Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $109.78 (+27.0%)
Spot @ $86.44

HSIC cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on HSIC, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $86.44 (52-wk range $63.04 - $92.18), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%